Scholarlink

<p>In this study, novel linear 3-(arylamino)naphtho[2,3-<i>b</i>]furan-2,4,9(3<i>H</i>)-trione derivatives has been synthesized <i>via</i> annulation reaction of 2-hydroxy-1,4-naphthoquinone with aromatic amines and glyoxylic acid monohydrate using <i>p</i>-TSOH as catalyst at ambient temperature for the first time. The mechanism proceeds <i>via</i> an initial intermolecular aldol condensation, subsequent Michael addition, and final intramolecular nucleophilic annulation. The linear or angular configurations of the products was confirmed through <sup>1</sup>-<sup>13</sup>&#xa0;C heteronuclear multiple-bond correlation (HMBC) analysis. To evaluate the inhibitory activity of the synthesized compounds, computational methods such as molecular docking and ADME analysis were employed. Compounds <b>4h</b> and <b>4i</b> displayed potent activity against tested estrogen receptor alpha (ERα) as compared to Doxorubicin.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel naphtho[2,3-b]furan-2,4,9(3H)-trione derivatives as potent ERα inhibitors: design, regioselective synthesis, HMBC-NMR characterization, in silico molecular Docking and ADME studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月31日

查看全文
  • Seyede Bita Sajjadi,
  • Abolfazl Olyaei,
  • Monir Shalbafan

摘要

In this study, novel linear 3-(arylamino)naphtho[2,3-b]furan-2,4,9(3H)-trione derivatives has been synthesized via annulation reaction of 2-hydroxy-1,4-naphthoquinone with aromatic amines and glyoxylic acid monohydrate using p-TSOH as catalyst at ambient temperature for the first time. The mechanism proceeds via an initial intermolecular aldol condensation, subsequent Michael addition, and final intramolecular nucleophilic annulation. The linear or angular configurations of the products was confirmed through 1-13 C heteronuclear multiple-bond correlation (HMBC) analysis. To evaluate the inhibitory activity of the synthesized compounds, computational methods such as molecular docking and ADME analysis were employed. Compounds 4h and 4i displayed potent activity against tested estrogen receptor alpha (ERα) as compared to Doxorubicin.